【レポートの概要（一部）】
1. Introduction to CD Antigens
2. Nomenclature & Classification of CD Antigens
3. Mechanism of CD Antigen Cancer Therapeutics
4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview
5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges
6. CD Antigen Cancer Therapeutics Future Prospects
7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II
8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II
9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II
10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical
11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical
12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II
13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight
14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III
15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II
16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II
17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical
18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical
19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight
20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II
21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration
22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I
23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical
24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II
25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I
26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight
27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II
28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II
29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II
30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I
31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II
32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II
33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical
34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I
35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I
36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight
37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight
38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical
39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight
40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical
41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I
42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II
43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight
44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II
45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight
46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I
47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight
48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight
49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended
50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor
【レポート販売概要】
■ タイトル：がんCD抗原阻害剤の世界市場及びパイプライン2015■ 英文：Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015
■ 発行日：42217
■ 調査会社：KuicK Research
■ 商品コード：KUIK51101
■ 調査対象地域：グローバル
- OCTG（油井管）の世界市場2016-2020About OCTG The global oil country tubular goods market pertains to the family of consumables consisting of drill pipe, casing, and tubing that are extensively utilized in the global oil and gas operations. They refer to a class of steel pipe products that have varied applications across the upstream oil and gas industry. These goods are seamless or welded; however, a new segment of pipes is slowly …
- スマートウェアラブルフィットネス及びスポーツ端末・サービスの世界市場2016-2020About Smart Wearable Fitness and Sports Devices Smart wearable fitness and sports devices are portable devices that can be fastened to the body of a user to monitor real-time fitness, heart rate, sleep statistics, calorie control, and provide valuable health insights. The mechanism of smart wearable devices is similar to smartphones and tablets. These devices are used in various sports such as gol …
- ワイヤレス電力伝送の世界市場予測（～2022年）：電磁誘導方式、磁界共振方式The overall wireless power transmission market is expected to be valued at USD 11.27 Billion by 2022, growing at a CAGR of 23.15%. The growth of this market is propelled by the factors such as the convenience offered by and consumer preference for wireless connectivity and need for effective charging systems. The inductive technology in the growth stage, while the magnetic resonance technology is …
- ガラス製包装容器（パッケージ）の世界市場2015-2019About glass packaging Glass packaging is used in the packaging of F&B, pharmaceuticals, chemicals, and cosmetics. Glass bottles and jars can be molded into a variety of shapes and dimensions. Its inert nature and ability to preserve products over a long period of time makes glass a popular choice for packaging in the F&B industry. Glass provides the aesthetic appeal required for certain products t …
- ICT調達動向：金融産業部門 – 企業のICT投資計画Why was the report written? To highlight the criteria on which financial market institutions select their IT providers as well as the roles which have influence while making IT purchasing decisions. What is the current market landscape and what is changing? Financial market institutions are keen to deploy their technologies on-site as they have to adhere to strict compliance regulations relating t …
- 世界の油脂市場のM&A動向（2014年6月）Synopsis The report provides a review of the mergers and acquisitions (M&As), partnering deals, and agreements entered into by companies active in the global oils and fats market during June 2014. Summary Using this report, dealmakers will effectively gain an insight into deal activity of the global oils and fats market throughout the month. Additionally, the report provides an overview of all the …
- RF MEMSデバイスの世界市場About RF MEMS RF MEMS are components that are integrated in electronic systems and provide RF functionality. Some of the types of RF MEMS components include CMOS integrable RF MEMS resonators and self-sustained oscillators, RF MEMS tunable inductors, RF MEMS switches, switched capacitors, and varactors. MEMS devices employed in RF applications are called RF MEMS. The term RF MEMS signifies the des …
- 2014年戦略提言：アメリカの家庭/セルフ検査市場This new 175-page report from Venture Planning Group provides analysis of the major home/self testing market segments, including diabetes (strips and meters), pregnancy, ovulation, and occult blood. The report presents trends, dynamics, size, growth, regulatory requirements, technologies, and competitive profiles.RationaleThe growing economic pressures on hospitals, coupled with advance …
- 複合イベント処理（CEP）の世界市場予測（～2020）MarketsandMarkets forecast the Complex Event Processing market size to grow from USD 1.28 Billion in 2015 to USD 4.95 Billion by 2020, at a compound annual growth rate (CAGR) of 31.1%. The adoption of device based computing and potential growth in demand for enterprise data worldwide are the main drivers of the CEP market. Presently, on-premise based deployment of CEP has the larger share than the …
- 韓国の発電市場2016：市場動向、制度、競争状況South Korea Power Market Outlook to 2030, Update 2016 - Market Trends, Regulations, and Competitive Landscape Summary This report elaborates South Korea's power market structure and provides historical and forecast numbers for generation, capacity and consumption up to 2030. Detailed analysis of the South Korea power market’s regulatory structure, import and export trends, competitive landscape, a …
- Radiculopathy：グローバル臨床試験レビューH1, 2013Radiculopathy Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Radiculopathy. It includes an overview of the trial numbers and their recruitment status as per the …
- 電気自動車（EV）の世界市場予測（～2030年）“Heavy investments from automakers in EVs and encouraging government policies and subsidies are significant factors for the growth of the electric vehicle market globally” The global electric vehicle market is estimated to grow from 3,269,671 units in 2019 to reach 26,951,318 units by 2030, at a CAGR of 21.1%. Increased emphasis on reduction in carbon emissions is expected to boost the market. How …
- 事業提携・ライセンシング・投資・M&A動向：March 2013（製薬業界）Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides …
- 世界のスマート鉄道市場：乗客情報システム、貨物情報システムなどThe demand for safe, fast, and reliable rail services continues to be the reason for concern for all the countries across the globe. Lack of operational efficiency and reliability, safety and security issues, and aging railway systems and practices are haunting various countries to bring about a change in their existing rail infrastructure. The global rail industry struggles to meet increasing dem …
- 業務用AV機器・サービスの世界市場2016-2020Pro AV refers to the audio-video products and services, which are used for various applications such as collaborative conferencing that include video, audio, web, and data conferencing, digital signage, command and control centers, tradeshow exhibitions, presentations, medical communications, virtual events, and corporate events. With the use of cloud and Internet, pro-AV solutions make quicker co …
